A proactive, interdisciplinary approach is essential to effectively manage the evolving challenges associated with 505(b)(2) medications. Implementing structured tools, including a crosswalk comparison tool, directory, and prioritization matrix, provided a systematic method to identify and monitor these products within a complex regulatory environment. Continued refinement will be necessary as CMS and Food and Drug Administration policies evolve, but this model offers a framework that may be adapted to different care settings.
Matsuda et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: